Mufg Securities Americas Inc. Makes New $451,000 Investment in Humana Inc. (NYSE:HUM)

Mufg Securities Americas Inc. acquired a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 1,778 shares of the insurance provider’s stock, valued at approximately $451,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. FPC Investment Advisory Inc. acquired a new position in shares of Humana during the fourth quarter worth about $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana during the fourth quarter worth about $33,000. Finally, Transce3nd LLC acquired a new position in shares of Humana during the fourth quarter worth about $38,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HUM. Barclays boosted their price objective on Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a research report on Friday, April 11th. Truist Financial lowered their price target on Humana from $325.00 to $305.00 and set a “hold” rating for the company in a report on Monday. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Raymond James raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Finally, Mizuho upped their price target on Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a report on Wednesday, April 9th. Seventeen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $286.81.

Humana Price Performance

Humana stock opened at $226.26 on Friday. Humana Inc. has a 12 month low of $212.45 and a 12 month high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business has a 50 day simple moving average of $263.20 and a 200-day simple moving average of $269.61. The stock has a market capitalization of $27.31 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analysts’ expectations of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.23 earnings per share. Equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.56%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s payout ratio is 25.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.